BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| 1 |
Apple
AAPL
|
+$487M |
| 2 |
Industrial Select Sector SPDR Fund
XLI
|
+$393M |
| 3 |
Microsoft
MSFT
|
+$380M |
| 4 |
Financial Select Sector SPDR Fund
XLF
|
+$349M |
| 5 |
iShares MSCI ACWI ETF
ACWI
|
+$312M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$1.26B |
| 2 |
Salesforce
CRM
|
+$765M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$368M |
| 4 |
Eli Lilly
LLY
|
+$255M |
| 5 |
AGN
Allergan plc
AGN
|
+$225M |
Sector Composition
| 1 | Technology | 18.31% |
| 2 | Consumer Discretionary | 8.56% |
| 3 | Healthcare | 8.43% |
| 4 | Financials | 7.4% |
| 5 | Communication Services | 7.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
JNCE
3151
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $6.03K | ﹤0.01% |
874
-4,187
| -83% | -$28.9K |
|
3152
Quad
QUAD
$336M
| $5.99K | ﹤0.01% |
1,844
-8,655
| -82% | -$28.1K |
|
3153
Princeton Bancorp
BPRN
$221M
| $5.98K | ﹤0.01% |
298
-1,434
| -83% | -$28.8K |
|
3154
Hawthorn Bancshares
HWBK
$225M
| $5.97K | ﹤0.01% |
341
-1,696
| -83% | -$29.7K |
|
3155
Nathan's Famous
NATH
$452M
| $5.96K | ﹤0.01% |
106
-810
| -88% | -$45.6K |
|
3156
ProShares Short S&P500
SH
$1.22B
| $5.93K | ﹤0.01% |
+66
| New | +$5.93K |
|
3157
Regional Management Corp
RM
$421M
| $5.92K | ﹤0.01% |
334
-2,328
| -87% | -$41.2K |
|
|
IIN
3158
DELISTED
IntriCon Corporation
IIN
| $5.87K | ﹤0.01% |
434
-2,112
| -83% | -$28.6K |
|
3159
Fortress Biotech
FBIO
$114M
| $5.86K | ﹤0.01% |
146
+133
| +1,023% | +$5.34K |
|
|
TREC
3160
DELISTED
Trecora Resources
TREC
| $5.86K | ﹤0.01% |
934
-5,730
| -86% | -$35.9K |
|
|
REV
3161
DELISTED
Revlon, Inc.
REV
| $5.85K | ﹤0.01% |
591
-1,946
| -77% | -$19.3K |
|
3162
Funko
FNKO
$185M
| $5.84K | ﹤0.01% |
1,007
-5,754
| -85% | -$33.4K |
|
|
PVLA
3163
Palvella Therapeutics, Inc. Common Stock
PVLA
$646M
| $5.83K | ﹤0.01% |
23
-173
| -88% | -$43.8K |
|
|
RPT
3164
Rithm Property Trust Inc.
RPT
$125M
| $5.81K | ﹤0.01% |
632
-4,734
| -88% | -$43.6K |
|
3165
Northrim BanCorp
NRIM
$509M
| $5.81K | ﹤0.01% |
231
-1,792
| -89% | -$45K |
|
3166
Stratus Properties
STRS
$161M
| $5.8K | ﹤0.01% |
293
-1,523
| -84% | -$30.2K |
|
3167
Peoples Bancorp of North Carolina
PEBK
$169M
| $5.8K | ﹤0.01% |
328
-1,169
| -78% | -$20.7K |
|
3168
South Plains Financial
SPFI
$651M
| $5.8K | ﹤0.01% |
407
-2,717
| -87% | -$38.7K |
|
3169
Fulgent Genetics
FLGT
$681M
| $5.79K | ﹤0.01% |
+362
| New | +$5.79K |
|
3170
EVI Industries
EVI
$360M
| $5.78K | ﹤0.01% |
266
-1,162
| -81% | -$25.2K |
|
|
ELOX
3171
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $5.76K | ﹤0.01% |
48
-147
| -75% | -$17.6K |
|
3172
Sasol
SSL
$4.53B
| $5.76K | ﹤0.01% |
747
-56
| -7% | -$432 |
|
3173
FS Bancorp
FSBW
$321M
| $5.75K | ﹤0.01% |
298
-2,206
| -88% | -$42.5K |
|
|
AAIC
3174
DELISTED
Arlington Asset Investment Corp.
AAIC
| $5.74K | ﹤0.01% |
1,934
-9,171
| -83% | -$27.2K |
|
3175
Lexicon Pharmaceuticals
LXRX
$403M
| $5.73K | ﹤0.01% |
2,874
-10,846
| -79% | -$21.6K |
|